Opioids
Purdue Pharma’s $7.4 Billion Opioid Settlement and Bankruptcy Filing
Purdue Pharma, Sackler family, opioid crisis, bankruptcy, settlement, OxyContin
Mallinckrodt, Endo set for $6.7B merger
pharmaceutical merger, opioid litigation, generics, injectables, synergies
Mallinckrodt and Endo Announce $6.7 Billion Merger to Create Diversified Pharmaceutical Leader
Pharmaceutical merger, Mallinckrodt, Endo, opioid litigation, generics, branded drugs, synergies
FDA Approves Label Changes for Indivior’s Sublocade, Enhancing Treatment Accessibility for Opioid Use Disorder
Sublocade, FDA approval, rapid initiation protocol, alternative injection sites, opioid use disorder treatment
FDA Approves Vertex’s Journavx: First Non-Opioid Pain Medication in Decades
Journavx, suzetrigine, non-opioid, acute pain, FDA approval, Vertex Pharmaceuticals, pain management, opioid alternative
Sackler Family and Purdue Pharma Agree to Enhanced $7.4 Billion Opioid Settlement
Sackler family, Purdue Pharma, opioid settlement, $7.4 billion, multistate agreement, opioid crisis, addiction treatment, recovery programs
FDA Approves Protega’s 10 mg Abuse-Deterrent Opioid Roxybond for Pain Management
FDA approval, Protega Pharmaceuticals, Roxybond, abuse-deterrent opioid, pain management, SentryBond technology
Vertex’s Non-Opioid Pain Drug, Suzetrigine (VX-548), Shows Promising Results in Phase III Trials, Aiming for FDA Approval
Non-opioid pain drug, Suzetrigine (VX-548), Vertex Pharmaceuticals, Phase III trials, acute pain, FDA approval, opioid alternative
Orexo’s Opioid Overdose Nasal Spray Fails FDA Review for Second Time
Orexo, OX124, FDA, Nasal Spray, Opioid Overdose, Naloxone, Human Factors Study, Technical Data
US Supreme Court Rejects Purdue’s Multibillion-Dollar Opioid Pact
US Supreme Court, Purdue Pharma, Opioid Settlement, Sackler Family, Bankruptcy, Opioid Crisis